Using MRI to improve diagnosis of brain damage from lung cancer treatment
Official title: Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Run by Assistance Publique - Hôpitaux de Paris · NCT05977803 · Data updated 2026-11-12
This study tests a new MRI method to see if it can better diagnose brain damage in lung cancer patients who have had radiation treatment and are facing complications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | Bevacizumab, chemotherapy, immunotherapy |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | February 15, 2024 |
| Main results expected | February 15, 2029 |
| Study ends | March 15, 2029 |
| Registry record updated | March 31, 2026 |
| Trial ID | NCT05977803 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with histologically confirmed lung cancer and brain metastases who have received radiotherapy.
✕Probably not a fit
Patients who are contraindicated for MRI or have severe cognitive impairments that prevent informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of the Chemical Exchange Saturation Transfer (CEST) MRI sequence in diagnosing radionecrosis in patients with brain metastases originating from lung cancer. It compares the diagnostic performance of CEST with the standard T2* infusion method following contrast injection. The study focuses on patients who have undergone stereotactic radiotherapy for brain metastases and are experiencing complications related to treatment. By improving diagnostic accuracy, the study seeks to enhance patient management and treatment outcomes.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses of radionecrosis, allowing for better-targeted treatments for patients with brain metastases from lung cancer.
How similar studies have gone: While there have been various studies on MRI techniques for diagnosing brain metastases, the specific use of the CEST sequence for radionecrosis is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \> 18 years of age * Histologically proven primary lung cancer * Histologically proven or not brain metastases * Irradiated metastases * Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy * Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI * Patients affiliated to a social security scheme Exclusion Criteria: * Opposition to the study * Contraindication to MRI * Refusal of imaging by the patient * Patient with state medical aid (unless exemption from affiliation) * Severe cognitive impairment making informed consent impossible * Patients under guardianship or deprived of liberty
Where it's running
-
Hôpital Bichat-Claude Bernard
Paris, France Recruiting
Study contacts
- Principal investigator: Augustin Gaudemer, MD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Augustin Gaudemer, MD
- Email: augustin.gaudemer@aphp.fr
- Phone: 01 40 25 76 13
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EarlyFDG PET after Radiotherapy to See Brain Metastases and Radionecrosis
This study tests whether a short FDG-PET scan after radiotherapy can help tell apart radionecrosis from recurring brain metastases in adults.
-
IL-8 receptor–modified CAR T cells for brain metastases in adults
This phase 1 study tests whether patient-derived, IL-8 receptor–modified CD70 CAR T cells can be safely given to adults with brain metastases.
-
Enhanced COPD care for people being checked for lung cancer
This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.
-
Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain
This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.
-
Molecular comparison of primary gastroesophageal cancers and their brain metastases
This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.
-
Imaging inflammation in primary and metastatic brain tumors with [C-11]-CS1P1 PET
This trial will test a new PET tracer, [C-11]-CS1P1, in adults with primary or secondary brain tumors to see if tracer patterns of inflammation relate to MRI, treatments, and clinical outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.